Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Unrecognized tax benefits (UTB) by Year
Unrecognized tax benefits (UTB) — Gross ending balance ($M) ($M)
Vertex Pharmaceuticals Unrecognized tax benefits (UTB): $852M in FY2025, up 20.7% from a year earlier. That is the highest of the 11 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Income Taxes — Unrecognized Tax Benefits).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized tax benefits (UTB) — Gross ending balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 852 | +20.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 706 | +14.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 616 | +34.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 460 | +212.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 147 | +70.0% | Form 10-K (filed 2025-02-13) ↗ |
| FY2020 | Dec 31, 2020 | 86.6 | +155.5% | Form 10-K (filed 2024-02-15) ↗ |
| FY2019 | Dec 31, 2019 | 33.9 | +73.8% | Form 10-K (filed 2023-02-10) ↗ |
| FY2018 | Dec 31, 2018 | 19.5 | +413.2% | Form 10-K (filed 2022-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 3.80 | – | Form 10-K (filed 2021-02-11) ↗ |
| FY2016 | Dec 31, 2016 | 0 | -100.0% | Form 10-K (filed 2020-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 0.40 | – | Form 10-K (filed 2019-02-13) ↗ |
Breakdown
What makes up unrecognized tax benefits (UTB)
- UTB rollforward — Additions for current year tax positions ($M)120 · FY2025
- UTB rollforward — Additions for prior year tax positions ($M)5.20 · FY2025
- UTB rollforward — Reductions for prior year tax positions ($M)5.70 · FY2025
- UTB rollforward — Settlements with taxing authorities ($M)6.30 · FY2025
- UTB rollforward — Expiration of statute of limitations ($M)10.7 · FY2025
- UTB — Portion that would impact effective tax rate if recognized ($M)437 · FY2025
- UTB — Accrued interest and penalties at period-end ($M)95.7 · FY2025
- UTB — Interest and penalties recognized in tax expense ($M)13.1 · FY2025
Cite this data
StockData. (2026). Vertex Pharmaceuticals Unrecognized tax benefits (UTB) ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/utb-tot
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.